

AMENDMENTS TO THE CLAIMS:

The listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A method of treating Parkinson's disease in a human in need of such treatment comprising: the administration to a human in need of such treatment of an antiparkinson therapeutic amount of an antiparkinson agent and an anti-inflammatory effective amount of a selective COX-2 inhibitor.

2. (Original) A method according to claim 1 wherein the antiparkinson agent is selected from an anticholinergic agent; a dopaminergic agent; a monoamine oxidase agent; and amantadine.

3. (Cancelled)

4. to 6. (Cancelled)

7. (Original) A method according to claim 2 wherein the dopaminergic agent comprises a dopamine precursor or a dopamine receptor agonist.

8. (Original) A method according to claim 2 wherein the dopaminergic agent comprises levodopa, bromocriptine, pergolide, pramipexole, cabergoline or ropinirole.

9. (Original) A method according to claim 2 wherein the monoamine oxidase agent comprises selegiline.

10. (Original) A method according to claim 2 further comprising a second an antiparkinson agent.

11. (Original) A method for the treating Hoehn & Yahr Stage I-III Parkinson's disease, which method comprises administration to a patient in need of such treatment of an amount of a selective COX-2 inhibitor and an amount of an anti-parkinsonism agent, such that together they provide effective treatment.

12. (Original) A method of relieving the symptoms of Parkinson's disease, which method comprises administration to a patient in need of such treatment of an amount of a selective COX-2 inhibitor and an amount of an antiparkinson agent, such that together they provide effective relief.

13. (Original) A method of treating Parkinson's disease, which method comprises administration to a patient in need of such treatment of an amount of a selective COX-2 inhibitor and an amount of an anti-parkinsonism agent, such that together the agents provide greater relief than that obtained by administration of the antiparkinson agent alone.

14. (Original) A method for ameliorating the progress of Parkinson's disease, which method comprises administration to a patient in need of such treatment of a therapeutically effective amount of a selective COX-2 inhibitor and an amount of an antiparkinson agent, such that together they provide effective amelioration.

15. (Original) A method for slowing the progress of Parkinson's disease, which method comprises administration to a patient in need of such treatment of a therapeutically effective amount of a selective COX-2 inhibitor and an amount of a antiparkinson agent, such that together they are effective in slowing the progress of the disease.

16. (Original) A method of treating Parkinson's disease in patients for which symptomatic relief by administration of an antiparkinson agent is not indicated which method comprises administration to a patient in need of such treatment of a therapeutically effective amount of a selective COX-2 inhibitor.

17. (Original) A method according to Claim 16 in wherein said patients have early stage Parkinson's disease and patients with minimal or mild symptoms of Parkinson's disease.

18. (Original) A method of for slowing the progress of Parkinson's disease, which method comprises administration to a patient in need of such treatment of a therapeutically effective amount of a selective COX-2 inhibitor.

19. (Cancelled)

20. (Presently amended) A method according to Claim 1, wherein the selective COX-2 inhibitor is rofecoxib (VIOXX®)-VIOXX.

21. (Presently amended) A method of treating Parkinson's disease in a human in need of such treatment according to claim 1 comprising: the administration to a human in need of such treatment of an antiparkinson therapeutic amount of pergolide, an antiparkinson therapeutic amount of selegiline and an anti-inflammatory effective amount of rofecoxib (VIOXX®)-VIOXX.